Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMB-101 in Healthy Volunteers and Patients With Active Rheumatoid Arthritis (RA)

Next Previous
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMB-101 in Healthy Volunteers and Patients With Active Rheumatoid Arthritis (RA)

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMB 101 IMBiologics (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; First in man
  • Sponsors IMBiologics

    • Most Recent Events

    • 05 Mar 2025 According to Navigator Medicines media release, data from this study will be presented at the American Academy of Dermatology (AAD) Annual Meeting, taking place in Orlando, Florida, from March 7-11, 2025.
    • 17 Jun 2024 According to IMBiologics media release, Phase 1a clinical trial of IMB-101 is expected to be completed soon, and the Phase 1b clinical trial for evaluating patients will begin in the second half of the year. From the Phase 1b clinical trial, the navigator will lead clinical development.
    • 28 Dec 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top